Description: Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
Home Page: azitrainc.com
21 Business Park Drive
Branford,
CT
06405
United States
Phone:
(203) 646-6446
Officers
| Name | Title |
|---|---|
| Mr. Francisco D. Salva | President, CEO & Director |
| Mr. Travis M. Whitfill M.P.H., Ph.D. | Co-Founder, COO & Director |
| Mr. Norman Staskey | CFO, Treasurer & Secretary |
Exchange: NYSE MKT
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.0055 |
| Price-to-Book MRQ: | 0.4455 |
| Price-to-Sales TTM: | 38.8186 |
| IPO Date: | 2023-06-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |